Everest Medicines Announces Inclusion of VELSIPITY® and XERAVA® in China's 2026 National Reimbursement Drug List
SHANGHAI, Nov. 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that VELSIPITY® (etrasimod arginine tablets) and XERAVA® (eravacycline hydrochloride for injection) have been included in the 2026 National Reimbursement Drug List (the "NRDL") for the first time. This inclusion will further improve the accessibility and affordability of VELSIPITY® and XERAVA®, enabling more patients to benefit from innovative treatments. The updated NRDL will take effect on January 1, 2027. In addition, NEFECON® (budesonide delayed-release capsules) will continue to be included in the updated NRDL.
VELSIPITY® (etrasimod arginine tablets) is China's first and only[i] selective sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of ulcerative colitis (UC). The inclusion of VELSIPITY® in the NRDL expands access to an innovative, once-daily oral treatment for UC that is recommended by clinical guidelines as a first-line therapy.
XERAVA® (eravacycline) is the world's first and only[i] fully synthetic fluorocycline antibiotic. It is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults and is characterized by a broad antimicrobial spectrum, potent antibacterial activity, confirmed clinical efficacy, and a favorable safety profile.
"We are happy to see the NRDL inclusion of VELSIPITY® and XERAVA®, which marks an important milestone for the Company," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "This reflects the recognition of the clinical value of these innovative medicines. Their inclusion will expand patient access to new treatment options for UC and cIAI while reducing the financial burden on patients.
We will continue to improve patient access to our innovative medicines through NRDL coverage, enabling more patients to benefit from these treatments.
NEFECON® has reached more patients with IgA nephropathy (IgAN) since its inclusion in the NRDL, with real-world evidence further reinforcing its clinical value as a first-line etiological treatment for IgAN."
VELSIPITY® was approved by China's NMPA in February 2026 for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
In the ENLIGHT UC study, the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, 51.9% of VELSIPITY®-treated patients achieved deep mucosal healing at week 40 of the maintenance period[1]. Five-year follow-up data show a favorable long-term safety profile[2]. The once-daily oral regimen requires no injection or infusion, facilitating at-home use and long-term outpatient management.
UC is a chronic, relapsing, non-specific inflammatory bowel disease that can significantly affect patients' quality of life and place a substantial burden on patients, their families and healthcare systems.
"We are very pleased to see VELSIPITY® included in the updated NRDL," said Professor Kaichun Wu, principal investigator for VELSIPITY®'s Asia clinical trial at the First Affiliated Hospital of AFMU, Treasurer of the World Gastroenterology Organisation (WGO), Vice President of the Asian Pacific Association of Gastroenterology (APAGE), and Vice President of the Chinese Society of Gastroenterology (CSG). "UC continues to present significant treatment challenges, with the number of patients in China projected to increase from approximately 980,000 in 2025 to 1.5 million by 2031[3],[4]. Patients often face inadequate treatment response, disease relapse and the need for long-term disease management. As a highly selective S1P receptor modulator, VELSIPITY® provides an innovative oral treatment option, with demonstrated efficacy in achieving deep mucosal healing and a favorable safety profile. Its once-daily oral administration offers convenience. The inclusion of VELSIPITY® in the NRDL is expected to improve patient access to this innovative treatment."
The World Health Organization (WHO) has included XERAVA® in its list of medically important antimicrobials.
Led by the Expert Committee on Clinical Use of Antimicrobials and Evaluation of Antimicrobial Resistance of the National Health Commission of China, the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline"[5] systematically analyzed 3,369 real-world patient cases from 231 hospitals across China[ii], providing further evidence of the efficacy and safety of XERAVA® in treating drug-resistant bacterial infections, including cIAI.
"Treating cIAI, particularly those involving drug-resistant bacteria, remains a significant clinical challenge," said Professor Yunsong Yu, Qiushi Distinguished Professor at Zhejiang University and Head of the Department of Infectious Diseases at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. "The inclusion of XERAVA® in the NRDL helps address the unmet clinical need for the treatment of cIAI caused by carbapenem-resistant pathogens, including carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE), particularly in cases involving mixed infections. As the world's first fully synthetic fluorocycline antibiotic, XERAVA® offers broad-spectrum activity against drug-resistant pathogens, including CRAB and CRE, with demonstrated clinical efficacy, high cure rates in cIAI caused by these pathogens, and a favorable safety and tolerability profile. Its inclusion in the NRDL is expected to enable more patients in China to benefit from it."
The clinical value of VELSIPITY® has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY® was also included in the 2025 American College of Gastroenterology (ACG) Clinical Guideline, the 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and the 2026 European Crohn's and Colitis Organization (ECCO) Guidelines[6-9].
XERAVA® has been recommended in multiple Chinese guidelines and expert consensus documents, including the Expert Consensus on the Multidisciplinary Management of Intra-Abdominal Infections, the Guidelines for the Diagnosis, Treatment, Prevention and Control of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli, the Chinese Expert Consensus on the Diagnosis, Treatment and Prevention of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections in Patients with Hematological Malignancies, and the Chinese Guidelines for the Clinical Application of Antibacterial Drugs for Febrile Neutropenia (2026). Internationally, XERAVA® has also been recommended in the Surgical Infection Society (SIS) Guidelines on the Management of Intra-Abdominal Infection, as well as in multiple global treatment guidelines issued by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), as a treatment choice for multi-drug resistant gram-negative bacterial infections including Carbapenem resistant organisms.
About VELSIPITY® (etrasimod arginine tablets)
VELSIPITY® (etrasimod arginine tablets) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4 and 5. China's National Medical Products Administration (NMPA) has approved VELSIPITY® on February 2, 2026, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Results from the ENLIGHT UC study(ES101002) demonstrated that the clinical remission rate after 12-week induction period followed by 40-week maintenance period reached 48.1%, and the mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%. As the largest Phase 3 registrational study in Asian patients with moderately to severely active UC, the study confirmed the efficacy and safety of VELSIPITY® with results published in The Lancet Gastroenterology & Hepatology. Results from the ELEVATE UC open-label extension demonstrated that continuous treatment with VELSIPITY® for up to 3 years resulted in 86.8% patients achieving clinical response among the observed cases, with both clinical remission and mucosal healing rates maintained at approximately 60%. Safety data extending up to five years from the global clinical study further confirm that VELSIPITY® is well tolerated and maintains a favorable and stable safety profile.
Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY® was also included in the American College of Gastroenterology (ACG) Clinical Guideline updated in June 2025, with strong recommendation supporting its use for both induction and maintenance treatment in patients with moderately to severely active UC.
Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, UK, Switzerland, Israel, Turkey, Serbia, Brazil, United Arab Emirates, Qatar, Republic of Ecuador, Mexico, Macau SAR, Singapore, Hong Kong SAR, the Chinese Mainland, South Korea, Taiwan region, China and Saudi Arabia for VELSIPITY® in the treatment of ulcerative colitis.
About XERAVA®
XERAVA® (Eravacycline), is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible Gram-positive, Gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates. XERAVA® is currently approved for the treatment of complicated intra-abdominal infections (cIAI) in the U.S., E.U., U.K., Singapore, the Chinese Mainland, Hong Kong SAR and Taiwan region, China. In March 2023, National Medical Products Administration (NMPA) of China approved New Drug Application (NDA) for XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI) in adult patients. The Company launched XERAVA® in July 2023 in the Chinese Mainland.
Since 2020, XERAVA® has been recommended in The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection and in multiple global treatment guidelines issued by Infectious Disease Society of America's (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) as a treatment choice for multi-drug resistant Gram-negative bacterial infections including Carbapenem resistant organisms. In addition, it was included in an expert consensus on the multi-disciplinary management of intra-abdominal infections by the Chinese Society of Surgery of Chinese Medical Association, Infectious Diseases Society for Evidence-based and Translational Medicine of Chinese Research Hospital Association and the Editorial Board of Chinese Journal of Surgery. In Feb. 2023, XERAVA® was also recommended in the Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant Gram-negative bacilli.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company owns a global manufacturing base of commercial scale in Jiashan, Zhejiang Province, and has established a comprehensive GMP production quality management system in accordance with China, EU, and WHO standards.
The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Its pharmaceutical distribution capabilities further complement its existing manufacturing and commercialization operations, supporting efficient product supply and delivery to the market.
Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion.
For more information, please visit the Company's website: www.everestmedicines.com.
Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Notes:
[i] As of November 2026
[ii] As of September 2024
References:
- K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0.
- D.T. Rubin, et al. ECCO 2026. Abstract ID: jjaf231.1256.
- Shao B, et al. Front Public Health. 2022;10:1032679.
- Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727.
- Expert Committee on Clinical Use of Antimicrobials and Evaluation of Antimicrobial Resistance of the National Health Commission. Final Report of the Comprehensive Evaluation Project on the Clinical Application of Eravacycline[R]. 2024.
- Singh S, Loftus EV Jr, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167(7):1307-1343.
- Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187-1224.
- Ooi CJ, Ling KL, Limsrivilai J, et al. Asian Pacific Association of Gastroenterology (APAGE) clinical practice guidelines on the use of small molecules and IL-23 p19 inhibitors in ulcerative colitis and Crohn's disease. J Gastroenterol Hepatol. 2026;41(7):2006-2029.
- Gisbert JP, Chaparro M, Verstockt B, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2026;20(7):jjag066.
- 発信企業・団体
- Everest Medicines
- 業種カテゴリ
- 医療・健康・介護
- 発表日時
- 2026-11-16 20:48 (JST) 原文: 2026-11-16 19:48 (+08:00)
- 原文
- 配信元のページを開く
本記事はPR Newswireより配信されたプレスリリースを原文のまま掲載したものです。 内容に関する責任は発信者に帰属し、当サイトは記載内容の正確性を保証しません。 掲載内容に関するお問い合わせは お問い合わせ よりご連絡ください。